Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
What Happened? A number of stocks fell in the afternoon session after a key industry player warned that changes to some insurance plans could slow U.S. proce...
A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Fin...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Over the past six months, Globus Medical’s shares (currently trading at $79.99) have posted a disappointing 10.1% loss, well below the S&P 500’s 10.7% gain. ...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Globus Medical’s first quarter delivered results ahead of Wall Street’s expectations, but the market reacted negatively, with shares declining over 5%. Manag...
